GOVX

GeoVax Labs Inc

GOVX, USA

GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms in the United States. The company is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. It also developing GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, the company offers GEO-MVA-MUC1, a vaccine candidate, which is in preclinical trial for the treatment of solid tumor cancers; GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-EMO1-Z, which is in preclinical trial for the treatment of Ebola Zaire; GEO-EMO1-S, which is in preclinical trial for the treatment of Ebola Sudan; GEO-MM01 treatment for marburg; and GEO-MVA for the treatment of Mpox and small pox. It has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; U.S. Department of Defense; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is headquartered in Smyrna, Georgia.

https://www.geovax.com

Stock Price

$ 0.00

0% decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
GOVX
stock
GOVX

Guidance Update: Why GOVX stock is favored by pension funds - July 2025 Spike Watch & Short-Term Trading Opportunity Alerts moha.gov.vn

Read more →
GOVX
stock
GOVX

An analyst sees good growth prospects for Geovax Labs Inc (GOVX) setenews.com

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

STRONG BUY

Target Price:

$9.625

Analyst Picks

Strong Buy

3

Buy

1

Hold

0

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Low

1.55

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-128.77 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-93.87 %

Low ≤ 2%

High ≥ 10%

Debt to Equity

-

Very High

0.37

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 3.28% of the total shares of GeoVax Labs Inc

1.

UBS Group AG

(0.7897%)

since

2025/06/30

2.

Vanguard Institutional Extnd Mkt Idx Tr

(0.4633%)

since

2025/07/31

3.

Vanguard Group Inc

(0.4541%)

since

2025/06/30

4.

Geode Capital Management, LLC

(0.4218%)

since

2025/06/30

5.

Fidelity Extended Market Index

(0.2717%)

since

2025/07/31

6.

Morgan Stanley - Brokerage Accounts

(0.1976%)

since

2025/06/30

7.

BlackRock Inc

(0.1087%)

since

2025/06/30

8.

Spartan Extended Market Index Pool F

(0.0824%)

since

2025/07/31

9.

State Street Corp

(0.0664%)

since

2025/06/30

10.

Fidelity Total Market Index

(0.0567%)

since

2025/07/31

11.

Fidelity Series Total Market Index

(0.0567%)

since

2025/07/31

12.

Northern Trust Corp

(0.046%)

since

2025/06/30

13.

Northern Trust Extended Eq Market Idx

(0.0424%)

since

2025/06/30

14.

NT Ext Equity Mkt Idx Fd - L

(0.0424%)

since

2025/06/30

15.

Moneta Group Investment Advisors Inc

(0.0394%)

since

2025/06/30

16.

Spartan Total Market Index Pool G

(0.0338%)

since

2025/07/31

17.

Extended Equity Market Fund K

(0.0209%)

since

2025/06/30

18.

Citigroup Inc

(0.0162%)

since

2025/06/30

19.

SBI Securities Co Ltd

(0.0138%)

since

2025/06/30

20.

NT Ext Eq Mkt Indx Fd DC Lending Tier 5

(0.012%)

since

2025/06/30

21.

HARBOUR INVESTMENTS, INC.

(0.011%)

since

2025/06/30

22.

NT Ext Eq Mkt Indx Fd DC Lend T3

(0.0101%)

since

2024/12/31

23.

Tower Research Capital LLC

(0.0069%)

since

2025/06/30

24.

NT Ext Equity Mkt Idx Fd - NL

(0.0037%)

since

2025/06/30

25.

NT Ext Equity Mkt Idx Fd - DC - NL - T2

(0.0028%)

since

2025/06/30

26.

State St US Extended Mkt Indx NL Cl C

(0.0027%)

since

2025/08/31

27.

Extended Equity Market Fund M

(0.0026%)

since

2025/06/30

28.

Bank of America Corp

(0.0025%)

since

2025/06/30

29.

Advisor Group Holdings, Inc.

(0.0016%)

since

2025/06/30

30.

SSgA U.S. Total Market Index Strategy

(0.0011%)

since

2025/03/31

31.

Wells Fargo & Co

(0.0005%)

since

2025/06/30

32.

Royal Bank of Canada

(0%)

since

2025/06/30

33.

Quaker Wealth Management, LLC

(0%)

since

2025/06/30

35.

FMR Inc

(0%)

since

2025/06/30

36.

Jane Street Group LLC

(0%)

since

2025/06/30

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2025-09-30

EPS Actual

-0.31

EPS Estimate

-0.265

EPS Difference

-0.045

Surprise Percent

-16.9811%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Potential Value Candidate(4)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(4.8)
GARP
Not Attractive for GARP(2.5)
Growth
Weak Growth Prospect(1)
Momentum
Moderate Momentum(3.5)
Net Net
Not Undervalued (Net-Net)(3)
Quality
Low Quality Business(2.5)
Value
Fair Value(6)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.

GeoVax Labs Inc (GOVX) Stock Details & Analysis - Finnton | Finnton